Wedbush Securities’s Tandem Diabetes Care TNDM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-5,902
Closed -$238K – 1241
2024
Q2
$238K Buy
+5,902
New +$246K 0.01% 984
2020
Q4
– Sell
-2,563
Closed -$291K – 971
2020
Q3
$291K Buy
+2,563
New +$269K 0.03% 630
2020
Q1
– Sell
-4,889
Closed -$291K – 1005
2019
Q4
$291K Sell
4,889
-1,197
-20% -$73.8K 0.03% 691
2019
Q3
$359K Sell
6,086
-1,678
-22% -$107K 0.04% 565
2019
Q2
$501K Sell
7,764
-280
-3% -$18.1K 0.05% 437
2019
Q1
$511K Sell
8,044
-3,344
-29% -$176K 0.05% 399
2018
Q4
$432K Sell
11,388
-1,686
-13% -$59.5K 0.06% 401
2018
Q3
$560K Sell
13,074
-10,253
-44% -$358K 0.06% 353
2018
Q2
$514K Sell
23,327
-9,097
-28% -$112K 0.06% 371
2018
Q1
$161K Buy
32,424
+2,915
+10% +$9.4K 0.02% 714
2017
Q4
$70K Buy
29,509
+10,621
+56% +$33.4K 0.01% 810
2017
Q3
$138K Buy
18,888
+8,871
+89% +$56.2K 0.02% 757
2017
Q2
$80K Buy
10,017
+1,833
+22% +$16.9K 0.01% 782
2017
Q1
$98K Buy
8,184
+450
+6% +$9.84K 0.01% 775
2016
Q4
$166K Buy
7,734
+3,807
+97% +$146K 0.02% 691
2016
Q3
$301K Buy
+3,927
New +$286K 0.04% 514

Other funds holding TNDM

Wedbush Securities's TNDM Position: Q3 2024 in Review

Wedbush Securities sold out of Tandem Diabetes Care (TNDM) in Q3 2024, closing a stake of 5,902 shares — an estimated $238K sold.

Wedbush Securities first reported a position in TNDM in Q3 2016 and held it in 16 quarters. The position peaked at $560K in Q3 2018. 332 funds tracked by Wall St. Rank hold TNDM as of Q3 2024.

  • Wedbush Securities reported no remaining Tandem Diabetes Care position as of Q3 2024 after selling out during the quarter.
  • Wedbush Securities sold 5,902 Tandem Diabetes Care shares in Q3 2024, an estimated $238K.
  • Wedbush Securities first reported a position in Tandem Diabetes Care in Q3 2016 and held it in 16 quarters.
  • Wedbush Securities's Tandem Diabetes Care position peaked at $560K in Q3 2018.
  • 332 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q3 2024.

Based on Wedbush Securities's 13F filing for Q3 2024, filed 8 Nov 2024.